Ribociclib (1)

Hortobagyi G.N, et al. Annals of Oncology, 2025, 36(2), 149-157.

A phase III clinical trial (NATALEE) investigated ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) for patients with HR-positive/HER2-negative early breast cancer. In this randomized study, 2549 patients received ribociclib (400 mg/day, 3 weeks on/1 week off for 36 months) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 60 months), while 2552 patients received NSAI alone. Men and premenopausal women additionally received goserelin (3.6 mg every 28 days). The primary endpoint was invasive disease-free survival (iDFS), with secondary endpoints including recurrence-free survival and distant DFS. After a median follow-up of 33.3 months, ribociclib plus NSAI significantly reduced recurrence risk (HR 0.749, 95% CI 0.628-0.892; P = 0.0012), with a 3-year iDFS of 90.7% versus 87.6% for NSAI alone. Safety outcomes remained consistent with previous profiles.

Pishnamazi M, et al. Case Studies in Thermal Engineering, 2025, 74, 106834.

A computational study explored the encapsulation of Ribociclib (Ribo) within polyethylene glycol (PEG)-functionalized zinc oxide (ZnO) nanoparticles to enhance drug delivery efficiency. Density functional theory (DFT) calculations and molecular dynamics (MD) simulations were employed to assess structural, electronic, and thermodynamic properties. Two stable configurations were identified, with Configuration II showing superior performance due to dual Zn-O coordination bonds (2.1-2.3 Å) and multiple hydrogen bonds (2.7-2.9 Å). Electronic structure analysis demonstrated a narrower energy gap (3.15 eV), increased dipole moment, and stronger charge transfer, while optical absorption spectra confirmed robust electronic coupling at 340-361 nm. MD simulations revealed higher structural stability with reduced RMSD fluctuations (1.5 Å) and consistent charge distribution. Thermodynamic profiling further supported Configuration II's prolonged release kinetics (τ = 280 s), establishing it as an optimal nanocarrier formulation for Ribociclib delivery.